Third-Party Peptide Testing: Who Tests, What Gets Measured, and How to Check a Lot

Genuine independent testing means an analytical laboratory with nothing riding on the outcome has measured the material and published its own report — and the claim only counts for anything when that laboratory is named, the report bears a date, and the lot number it cites is one you can actually purchase. Anything else sold as third-party testing amounts either to in-house quality control under a name it has borrowed, or to a legitimate report on a batch that has long since gone. This guide sets out who performs these analyses, which ones answer which questions, how a sample submitted by a vendor differs from one bought blind, and how to check a report against the vial in front of you.

Three tiers of testing, and only one is truly independent

The boundary most often blurred is between the second and third rows. When a vendor picks which vial goes off for analysis, it controls precisely the variable the test was supposed to measure. Only programmes that buy from public listings anonymously actually address the question a purchaser has in mind. Contract-lab results published by a vendor do corroborate its certificate of analysis usefully — they simply do not demonstrate consistency across retail stock.

What these analyses actually determine

The first three are all that most published independent reports include. That ordering makes sense, since purity, identity and content are what change an experiment's outcome — but it also means "third-party tested" rarely extends to sterility or endotoxin, and should never be read as though it did.

Worked example: interpreting a quantity result properly

Of all these analyses, this is the one most frequently misreported — in both directions.

1. What the report says. Quantitative HPLC finds 8.6 mg of peptide in a vial labelled 10 mg, and headlines describe a 14% shortfall.
2. Remember the salt. Peptides made synthetically are isolated as salts. For a peptide with several basic residues, an acetate salt typically contributes 5–12% of the mass as counter-ion, and residual water left after lyophilization adds a further 2–8%.
3. Run the numbers. Dividing 8.6 by 10 gives 86% net peptide content, comfortably within the normal 70–90% band. The vial is not short: it holds 10 mg of powder containing 8.6 mg of peptide — precisely what an accurate COA would have stated.
4. When it really is a shortfall. Should the COA claim 95% net peptide content while an independent assay finds 86%, that is a genuine discrepancy of 0.9 mg per vial and worth taking up. The problem lies in the mismatch between claim and measurement, not in the number by itself.
5. The downstream consequence. Reconstituting such a vial in 2 mL yields 4.3 mg/mL of peptide rather than 5 mg/mL — a 14% error propagating into every concentration and every molarity you calculate from it.

In short, a quantity figure can only be interpreted next to a stated net peptide content. On its own, 8.6 mg means nothing definite.

Checking a report against the vial you hold

1. Match the lot. The lot number on the vial has to appear on the report — the lot, not merely the product name.
2. Look at the dates. Analysis should fall after manufacture and before expiry. A report predating the lot it purportedly describes is, at best, a filing mistake.
3. Establish where the sample came from. The report ought to say whether the laboratory received it from the manufacturer, from a distributor, or bought it. Silence on this point means assume it was submitted.
4. Read the chromatogram rather than the summary. Purity is the product of integration, so confirm the trace is included, the column and gradient are specified, detection sits at 214 nm or another justified wavelength, and the run lasted long enough for late-eluting impurities to show. The method for reading one is in HPLC purity explained.
5. Verify identity independently. For a small peptide, observed mass should fall within a fraction of a dalton of theoretical. See mass spectrometry and peptide identity.
6. Compare with the vendor's COA. Two documents covering one lot ought to agree within analytical variability, normally well inside a single percentage point on purity. A two-point divergence deserves a question.
7. For blends, insist on per-component figures. One purity number cannot characterise a multi-component vial; see blends vs single vials.

The limits of independent testing

• It says nothing about the following lot. A report covers one batch, and only repeated testing can demonstrate consistency between batches.
• It says nothing about stability. Purity at release reveals nothing about purity after nine months in a warm warehouse.
• It says nothing about biological activity. A clean trace and the right mass do not show that a peptide folds, binds or signals; cyclic and disulfide-bonded peptides can be chemically correct yet conformationally wrong.
• It says nothing about legal status.
• And it says nothing a vendor could not have selected for, if the vendor chose the sample.

Putting this to practical use

Treat an independent report as one piece of evidence rather than a final verdict. The strongest case a buyer can build combines a lot-matched vendor COA carrying both a chromatogram and MS data, an explicit net peptide content, and — where one exists — an independent report on that same lot from a blind purchase. Agreement between all three means the material is well characterised; disagreement is itself the result worth noting. Broader supplier assessment is covered in the vendor checklist, with further questions answered in the purity, COA and testing FAQ.